VOLITIONRX LTD (VNRX)

Current Report Filed: 2026-04-23

Key Insights

VolitionRx received notice of non-compliance with NYSE American listing standards across three separate equity thresholds ($2M, $4M, and $6M requirements), indicating significant financial distress and accumulated losses over multiple fiscal years.
The company has been granted until August 6, 2027 to regain compliance with listing standards, during which it remains listed but subject to periodic NYSE American review; failure to demonstrate sufficient progress or achieve compliance could trigger delisting proceedings.
The company's equity position has deteriorated to the point where it is ineligible for any exemptions (including the $50M market cap exemption), suggesting market capitalization has declined substantially and financial metrics are severely compromised.
The acceptance of the remediation plan provides a 16-month runway, but the company faces significant execution risk in restructuring operations and finances while competing in the healthcare diagnostics market with limited apparent resources.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Terig Hughes, who is the Chief Financial Officer of VolitionRX Ltd (VNRX), has acquired 49,200 shares of the company's common stock through the vesting of restricted stock units (RSUs).
The RSUs were awarded in March 2025 and were subject to the achievement of certain corporate performance goals and time-based vesting. A portion of the RSUs (49,200) vested, while the remaining 114,800 RSUs were cancelled.
The vested RSUs will be settled in shares of the company's common stock, increasing the reporting person's direct beneficial ownership to 482,970 shares.

Insider Trading Filed: 2026-01-23

Key Insights

Ethel Rubin, a director of VolitionRX Ltd (VNRX), acquired 12,000 shares of the company's common stock on January 22, 2026 through the vesting of restricted stock units (RSUs).
The RSU grant was part of Rubin's compensation, with certain performance goals met resulting in the vesting of 12,000 shares. The remaining 28,000 RSUs did not vest and were cancelled.
Rubin's ownership of VNRX shares increased to 74,948 shares following this acquisition, indicating continued insider investment in the company.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Guy Archibald Innes, acquired 12,000 shares of VolitionRX Ltd (VNRX) common stock through the vesting of restricted stock units (RSUs) on January 22, 2026.
Innes also holds indirect beneficial ownership of a significant number of VNRX shares through various trusts and family members, totaling over 2.3 million shares.
The insider buying activity and substantial existing ownership position indicate Innes' confidence in the company's prospects and potential upside for the stock.

Insider Trading Filed: 2026-01-23

Key Insights

Gael Forterre, the Chief Commercial Officer of VolitionRX, acquired 38,100 shares of the company's common stock through the vesting of restricted stock units (RSUs). This indicates insider confidence in the company's prospects.
Forterre also holds an indirect beneficial ownership of 37,500 shares through his spouse and Armorica Partners, LLC, further demonstrating his commitment to the company.
The vesting of RSUs is subject to the achievement of certain corporate performance goals, suggesting the company's management is focused on driving the business forward.

Insider Trading Filed: 2026-01-23

Key Insights

Insider Cameron John Reynolds acquired 74,700 shares of VolitionRX (VNRX) stock through the vesting of restricted stock units, indicating his continued confidence in the company's prospects.
Reynolds' total direct and indirect beneficial ownership increased to over 3.6 million shares, demonstrating his significant stake in the company.
The partial vesting and cancellation of the remaining RSUs suggests the company met some, but not all, of its performance goals, potentially signaling a mixed operational outlook.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Alan Colman, was awarded 40,000 restricted stock units (RSUs) in 2025 under the company's 2024 Stock Incentive Plan, with certain performance goals met resulting in 12,000 RSUs vesting.
The remaining 28,000 RSUs did not vest and were cancelled, indicating that the company did not fully meet the performance goals originally set.
The vested RSUs are subject to a 3-year time-based vesting schedule, with 4,000 units vesting annually, aligning the reporting person's incentives with long-term shareholder value creation.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Timothy I. Still, was awarded 300,000 restricted stock units (RSUs) in March 2025, of which 90,000 RSUs have vested based on the achievement of certain performance goals.
The remaining 210,000 RSUs did not vest and were cancelled in June 2025 and January 2026, indicating that some of the performance goals were not met.
The vested RSUs will be settled in shares of the company's common stock, with the shares vesting in equal installments over a 3-year period from March 2026 to March 2028.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Ann-Louise Batchelor, the Group Chief Marketing Officer of VolitionRX Ltd (VNRX), acquired 33,900 shares of common stock on January 22, 2026 as part of a restricted stock unit (RSU) award that vested.
The RSUs were granted on March 17, 2025 and were subject to the achievement of certain corporate performance goals, as well as a 3-year time-based vesting schedule.
The reporting person also holds an additional 29,406 shares of common stock indirectly through her spouse.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Phillip Barnes, was awarded 40,000 restricted stock units (RSUs) in March 2025, of which 12,000 RSUs vested in January 2026 upon meeting certain performance goals.
The remaining 28,000 RSUs did not vest and were cancelled, indicating the reporting person's compensation was tied to specific company performance metrics.
The vested RSUs are subject to a 3-year time-based vesting schedule, with the first 4,000 shares vesting in March 2026, providing an ongoing incentive for the reporting person to remain with the company.

Insider Trading Filed: 2026-01-23

Key Insights

The CEO of VolitionRX, Salvatore Thomas Butera, has acquired 53,400 shares of the company's stock, indicating his confidence in the company's future performance.
The CEO's acquisition of these shares is part of a vesting schedule for restricted stock units (RSUs) previously awarded, which suggests the company is implementing long-term incentive plans to align management's interests with shareholders.
The CEO also disposed of 99,350 shares, potentially for personal reasons, but still maintains a significant direct ownership stake in the company.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Rodney Gerard Rootsaert, was awarded 94,000 restricted stock units (RSUs) under the company's 2024 Stock Incentive Plan, of which 28,200 RSUs vested due to the achievement of certain corporate performance goals.
The remaining 65,800 RSUs did not vest and were cancelled, indicating the company may have missed some of its performance targets.
Rodney Gerard Rootsaert holds shares of the company both directly (165,458 shares) and indirectly through his controlling interest in Concord International, Inc. (1,007,718 shares), suggesting significant insider ownership.

Insider Trading Filed: 2026-01-23

Key Insights

Jacob Vincent Micallef, the Chief Scientific Officer of VolitionRX, has been granted 35,400 restricted stock units (RSUs) that have vested, indicating the company's confidence in his leadership and contributions.
Micallef also holds 55,000 shares indirectly through his spouse and 38,113 shares indirectly through Borlaug Limited, suggesting his alignment with the company's long-term success.
The vesting of the RSUs is subject to a three-year time-based schedule, aligning Micallef's incentives with the company's sustained performance over the long term.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Nicholas Plummer, was awarded 149,000 restricted stock units (RSUs) under the company's 2024 Stock Incentive Plan, of which 44,700 RSUs have vested based on the achievement of certain performance goals.
The vested RSUs are subject to a 3-year time-based vesting schedule, with 14,900 units vesting each year on March 17, 2026, 2027, and 2028.
The remaining 104,300 RSUs did not vest and were cancelled, indicating that the company did not fully meet all of the performance goals.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Mickie Henshall, was awarded 40,000 restricted stock units (RSUs) on March 17, 2025, of which 12,000 have vested due to the achievement of certain corporate performance goals.
The remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026.
The vested 12,000 RSUs are subject to a 3-year time-based vesting schedule, with 4,000 units vesting annually on March 17, 2026, 2027, and 2028, respectively.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Kim Nguyen, was awarded 40,000 restricted stock units (RSUs) under the company's 2024 Stock Incentive Plan, of which 12,000 RSUs vested due to the achievement of certain corporate performance goals.
The remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.
The vested RSUs are subject to a 3-year time-based vesting schedule, with 4,000 units vesting on each of March 17, 2026, 2027, and 2028.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Jasmine Kway, received a grant of 140,000 restricted stock units (RSUs) in March 2025 under the company's 2024 Stock Incentive Plan, of which 42,000 RSUs vested based on the achievement of certain performance goals.
The remaining 98,000 RSUs were cancelled due to unmet performance goals, indicating the company may have faced challenges in achieving its targets.
Kway, who is the CEO of the company's Singapore subsidiary, has a direct ownership of 245,614 shares in the company, as well as an additional 10,400 shares held indirectly through her spouse.

Current Report Filed: 2026-01-08

Key Insights

VolitionRx Limited entered into an amended and restated securities purchase agreement with Lind Global Asset Management XII LLC, providing additional financing of $2 million in exchange for a senior secured convertible promissory note and a common stock purchase warrant.
The amended agreement builds upon a previous securities purchase agreement from May 2025, further strengthening VolitionRx's financial position and flexibility.
The financing terms include customary representations, warranties, and covenants, as well as an ownership limitation and potential requirement for stockholder approval on the issuance of certain shares.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information